ArticleBMC pulmonary medicine2026
Incidence and prevalence of interstitial lung diseases in Norway: analysis of the national Norwegian patient registry.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInterstitial lung diseases (ILDs) are progressive chronic lung diseases associated with poor prognosis despite available disease-modifying therapy. Reported incidence and prevalence of ILD varies, and few studies have described epidemiology across the range of ILD subtypes in complete population-based cohorts. This study aimed to estimate incidence and prevalence of ILD, overall and by subtype, in a complete nationwide cohort from Norway.
methodsThe Norwegian Patient Registry and Norwegian Prescribed Drug Registry were used to identify all patients with diagnosis codes identifying an ILD between 2011 and 2023. Using diagnosis code-based algorithms adapted from previous studies, the incidence and prevalence of ILD subtypes was estimated overall by year, and by subgroups defined by age and sex.
resultsUsing a broad definition, the overall prevalence of ILD in Norway has increased to over 450 cases per 100,000 from 2012 to 2023. The prevalence of idiopathic pulmonary fibrosis (IPF) has increased to 46 per 100,000 and prevalence of connective tissue disease related ILD (CTD-ILD) has increased to nearly 42 per 100,000. Current estimates of incidence ranged from about 1 per 100,000 for hypersensitivity pneumonitis, to about 5 per 100,000 for CTD-ILD, to 8-10 per 100,000 for IPF.
conclusionsIncidence and prevalence of ILDs in Norway are comparable to published reports from other regions. The prevalence of ILDs in Norway appears to be increasing substantially.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.